determine the significance of the change in pyloric dimensions from birth to presentation with infantile hypertrophic pyloric stenosis.
Results
A total of 1400 consecutive newborn infants had pyloric dimensions measured at routine postnatal examination. Nine of these infants subsequently presented to this hospital with infantile hypertrophic pyloric stenosis, which in all cases was confirmed by surgery. The pyloric dimensions recorded are summarised in the table.
The initial pyloric dimensions of the nine infants who presented with infantile hypertrophic pyloric stenosis were no different from the other 1391 healthy newborns. However, there was a highly significant increase (p<0-001) in the size of the Plasma aldosterone and renin activity A M SCAMMELL AND M J DIVER* Institute of Child Health and *Subdepartment of Endocrine Pathology, University of Liverpool SUMMARY Eight infants had paired measurements of plasma aldosterone and plasma renin activity while being treated for congestive heart failure. There is parallelism with aldosterone and renin activity in the presence of a hyperactive reninangiotensin-aldosterone system. Six patients had plasma renin activity and plasma aldosterone measured after commencing captopril and we have shown biochemical blockade of the reninangiotensin-aldosterone system.
We have recently reported raised plasma renin activity in infants being treated for congestive heart failure due to congenital heart disease.1 In that study we were unable to report the results of plasma aldosterone because concentrations fell outside the range of the assay in most instances. We have performed an additional study to determine whether parallelism between plasma renin activity and plasma aldosterone, which has been described in normal 140 Archives of Disease in Childhood, 1988, 63 system can be blocked by using an angiotensin converting enzyme inhibitor.
Patients and methods
Eight patients had coincidental measurement of plasma renin activity and plasma aldosterone. Five of these patients had sampling on three separate occasions over a period of four weeks, one patient on two occasions, and two patients on a single occasion. The eight infants, at the time of the first sampling, had an age range of 19 to 111 days and their mean (SD) weight was 3330 (400) g. All the patients had congestive heart failure due to congenital heart disease with left to right shunts and were receiving diuretics.
Other criteria for inclusion in the study, the sampling conditions, and the method of estimation of plasma renin activity were as previously reported. 1 Plasma aldosterone was measured by direct radioimmunoassay using a 'Coat-a-Count' kit with 125I aldosterone label (Diagnostic Products Ltd).
The antialdosterone antibody is coated on the walls of the assay tubes thus achieving solid phase separation of the bound and unbound fractions. Both intra-assay and interassay precision is less than 10% throughout the range of the assay. Samples with expected aldosterone concentrations greater than the working range of the assay were diluted in zero calibrator. This procedure had previously been validated by serial dilution of a high level sample that displayed parallelism with the dose response curve. One ml of whole blood was required for each of the assays.
Six patients, including two patients in the first study, were given captopril for treatment of their heart failure. The standard regimen in use at the Royal Liverpool Children's Hospital for initiating treatment was followed. Oral captopril was introduced at 025 mg/kg/dose three times daily. Increments of 0-25 mg/kg were made each day up to a maximum of 1 mg/kg/dose. Plasma renin activity and plasma aldosterone were measured after at least four days on the maximum dose. The same conditions were employed for blood sampling but in addition the sample was timed at two hours after the dose of captopril.
Results
A total of 14 paired plasma renin activity and plasma aldosterone values were obtained in the first part of the study. Three patients from the first batch of assays (6, 7, and Outside standards range: >3300 pmol/l; *=patients whose plasma aldosterone assays were performed without dilution. 
Discussion
This study has shown that there is parallelism with plasma renin activity and plasma aldosterone when there is hyperactivity of the renin-angiotensinaldosterone system in infants in heart failure. Although five plasma aldosterone samples were above the range of the assay, these corresponded with high plasma renin activity values and tend to support our conclusion. Previous studies of normal infants have shown good correlation with plasma renin activity and plasma aldosterone in the normal range.2 In older children of widely varying ages with salt depleting conditions there is a rise of both plasma renin activity and plasma aldosterone.3 By contrast exchange transfusion with acute blood volume loss results in increased plasma renin activity but no parallel rise in plasma aldosterone.4 In our study the patients were in a stable state compared with those undergoing exchange transfusion.
Plasma aldosterone and renin activity 141 The effect of captopril is to block the conversion of angiotensin I to angiotensin II. The latter is one stimulus to the production of aldosterone and our study would suggest it is the major stimulus in infants in heart failure. We have shown that captopril at a dose of 1 mg/kg can effectively block this hormone system. Further studies of infants being treated for heart failure are required to determine the minimum dose required for effective blockade. 
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